Latest Conference Articles

Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma

Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.

Talquetamab Plus Teclistamab Demonstrates Durable Responses in Triple Class–Exposed R/R Myeloma

Combining talquetamab with teclistamab demonstrated responses even among those with extramedullary disease in the RedirecTT-1 trial.

Radium-223 Before Docetaxel Demonstrates Better QOL in mCRPC, With No Difference in Survival

D-VRd Extends PFS in Newly Diagnosed Multiple Myeloma Subgroups

D-VRd induction and consolidation therapy displayed a PFS benefit vs VRd in high-risk subgroups of patients with newly diagnosed multiple myeloma.

Belantamab Mafodotin Plus VRd Demonstrates Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma

Belantamab mafodotin-based combination appears to improve responses over time in those with transplant-eligible newly diagnosed multiple myeloma

Experts Share Intriguing Early-Phase Sarcoma Studies From the 2024 ESMO Congress

Read about the early-phase sarcoma studies presented at the 2024 ESMO Congress that experts are keeping their eyes on.

Adjuvant Pembrolizumab Prolongs DFS Regardless of PD-L1 or Nodal Status in High-Risk MIBC

Adjuvant pembrolizumab generated a DFS benefit vs observation in patients with high-risk muscle-invasive bladder cancer after radical surgery.

Breastfeeding During Endocrine Therapy Interruption Is Feasible, Does Not Adversely Affect Recurrence Rates in HR+ Breast Cancer

Patients with HR-positive breast cancer who conceived during a break from endocrine therapy found breastfeeding feasible and safe.

NKT2152 Data Reinforce the Importance of HIF2α Inhibition in Advanced Clear Cell RCC

The novel oral HIF2α inhibitor NKT2152 elicited encouraging responses in patients with previously treated advanced clear cell renal cell carcinoma.

CheckMate-9ER Post-Hoc Analysis Seeks to Identify Efficacy Biomarkers for Nivolumab/Cabozantinib in RCC

Elevated fucosylation and sialylation of serum proteins were negative prognostic factors in RCC after treatment with nivolumab plus cabozantinib or sunitinib.

Elacestrant Plus Abemaciclib Demonstrates Clinical Benefit in Pretreated ER+/HER2– Metastatic Breast Cancer

Elacestrant plus abemaciclib demonstrated clinical activity and manageable safety in pretreated ER+/HER2– metastatic breast cancer.

Experts Highlight Top Findings From the 2024 IASLC World Conference on Lung Cancer

Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.

Lenvatinib Plus Pembrolizumab Affords Deep and Durable Responses in Endometrial Cancer

Lenvatinib plus pembrolizumab led to tumor responses regardless of mismatch repair–proficient status, histology, and prior adjuvant therapy.

Dato-DXd Demonstrates Efficacy, Safety in Platinum-Resistant Ovarian and Endometrial Cancers

Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.

Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC

Ipilimumab given in combination with nivolumab met the primary end point of 12-month OS rate vs SOC in patients with nccRCC in the SUNNIFORECAST trial.

Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC

Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.

Neoadjuvant Chemotherapy Could Enhance Organ Preservation in Nasal and Paranasal Sinus Squamous Cell Carcinoma

Neoadjuvant chemotherapy improved organ preservation in nasal and paranasal sinus squamous cell carcinoma.

Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups

Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status

Fianlimab plus cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma.

Several IO Combos Miss Efficacy Target in NSCLC, But Clinical Benefit Seen With 2 Combos

Durvalumab plus monalizumab and durvalumab plus ceralasertib showed promising long-term benefits in advanced NSCLC.

GigaPath AI Model May Predict Cancer Mutations, Tumor Mutation Burden in Lung, Other Cancers

AI models like GigaPath may pave the way for other predictive models in cancer, as it deciphers diagnoses and mutations in a more granular method.

AMG 193 Shows Preliminary Clinical Activity in MTAP-Deleted Solid Tumors

AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses and an acceptable safety profile across patients with MTAP-deleted solid tumors.

Nonoperative Management Maintains DFRS, Promotes Organ Preservation in pMMR Rectal Cancer

In the NO-CUT trial, 97% of patients with pMMR locally advanced rectal cancer sustained distant relapse-free survival with nonoperative management.

Inavolisib Demonstrates Safety, Disease Control in PIK3CA-Mutated Solid Tumors

Inavolisib demonstrated a favorable safety profile and generated disease control in patients with tumors harboring PIK3CA mutations.

Dr Popat on OS Outcomes With Amivantamab Plus Chemotherapy in EGFR-Mutated, Advanced NSCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.

Darolutamide Plus ADT Improves rPFS in mHSPC

Darolutamide plus ADT shows PFS benefit without docetaxel in metastatic hormone-sensitive prostate cancer.

Abemaciclib/ET Combo Improves Responses vs Chemo in Aggressive HR+/HER2– Breast Cancer

Frontline abemaciclib plus ET demonstrated a superior ORR vs chemotherapy in HR+/HER2– advanced breast cancer with aggressive disease characteristics.

Multivariate Analysis Provides Additional Insight on Efficacy of 177Lu-Dotatate in GEP-NETs

Lutetium Lu 177 dotatate shows consistent efficacy over high-dose octreotide in advanced GEP-NETs, according to data from the NETTER-2 trial.

Durvalumab/Tremelimumab Sustains OS Benefit in Unresectable HCC

Tremelimumab plus durvalumab sustained an overall survival improvement in unresectable hepatocellular carcinoma.

Adjuvant Ribociclib Sustains DFS, DDFS Benefit in HR+/HER2– Breast Cancer

Adding ribociclib to a NSAI in the adjuvant setting prolonged invasive and distant disease-free survival in HR-positive, HER2-negative early breast cancer.